TickerFacts.

Neogen Corp (NEOG): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2016-05-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$1.25B
As of 2026-05-31
-4.1%
3-year compound annual growth
+73.5%
5-year compound annual growth
+39.2%
10-year compound annual growth
$1.42B2011-05-31: $30.68M2012-05-31: $32.55M2013-05-31: $32.27M2014-05-31: $39.00M2015-05-31: $41.22M2016-05-31: $45.78M2017-05-31: $56.65M2018-05-31: $57.83M2019-05-31: $57.84M2020-05-31: $72.00M2021-05-31: $79.81M2022-05-31: $105.56M2023-05-31: $1.42B2024-05-31: $1.40B2025-05-31: $1.37B2026-05-31: $1.25B$1.25B
2011-05-31 Total Liabilities (USD) 2026-05-31
Period endedTotal LiabilitiesChange YoYSource filing
2026-05-31$1.25B-8.7%2026-07-30, Balance as of period end
2025-05-31$1.37B-2.3%2026-07-30, Balance as of period end
2024-05-31$1.40B-1.1%2025-07-30, Balance as of period end
2023-05-31$1.42Bn/m2024-07-30, Balance as of period end
2022-05-31$105.56M+32.2%2023-08-15, Balance as of period end
2021-05-31$79.81M+10.8%2022-07-27, Balance as of period end
2020-05-31$72.00M+24.5%2021-07-30, Balance as of period end
2019-05-31$57.84M0.0%2020-07-30, Balance as of period end
2018-05-31$57.83M+2.1%2019-07-30, Balance as of period end
2017-05-31$56.65M+23.8%2018-07-27, Balance as of period end
2016-05-31$45.78Mn/c2017-07-28, Balance as of period end
2015-05-31$41.22M+5.7%2016-07-29, Balance as of period end
2014-05-31$39.00M+20.9%2015-07-30, Balance as of period end
2013-05-31$32.27M-0.8%2014-07-30, Balance as of period end
2012-05-31$32.55M+6.1%2013-07-30, Balance as of period end
2011-05-31$30.68Mn/a2012-07-30, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Neogen Corp (NEOG)2026-05-31$1.25B-8.7%
Myriad Genetics Inc (MYGN)2025-12-31$338.60M+3.7%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.14B+27.5%
QuidelOrtho Corp (QDEL)2025-12-28$3.85B+11.9%
Idexx Laboratories Inc (IDXX)2025-12-31$1.75B+2.8%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$170.73M-46.5%
Alpha Teknova, Inc. (TKNO)2025-12-31$34.81M-4.3%
Immucell Corp (ICCC)2025-12-31$15.48M-12.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$12.39M+53.8%

Compare NEOG, MYGN, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗